Literature DB >> 30955955

Acute type I aortic dissection with or without antegrade stent delivery: Mid-term outcomes.

Ourania Preventza1, Jacqueline K Olive2, Jane L Liao2, Vicente Orozco-Sevilla3, Katherine Simpson2, Meredith R Rodriguez4, Matt D Price4, Benjamin Y Cheong5, Subhasis Chatterjee2, Kim I de la Cruz3, Hiruni S Amarasekara4, Scott A LeMaire6, Joseph S Coselli3.   

Abstract

OBJECTIVE: We determined the effect of antegrade stent delivery in the descending thoracic aorta on short- and mid-term clinical and imaging outcomes for patients who underwent repair of acute DeBakey type I aortic dissection.
METHODS: Outcomes were evaluated for 178 patients who underwent acute type I aortic dissection between 2005 and 2016 (standard repair, n = 115 [64.6%]; antegrade stent delivery, n = 63 [35.4%]). Propensity score match and multivariable analyses were performed to assess outcomes.
RESULTS: The stent and standard repair groups had similar rates of operative mortality (30-day or in-hospital) (12.7% vs 17.4%, P = .41), persistent stroke (6.3% vs 5.3%, P = .75), and persistent paraplegia/paraparesis (1.6% vs 0.9%, P = 1.0). Propensity score match analysis indicated that the operative mortality rate was higher in the standard repair group (P = .059), which the multivariable analysis confirmed. The persistent stroke rate was nonsignificantly higher in the stent group (P = .66). Persistent paraplegia/paraparesis rates were similar in both groups (P = 1.0), and the overall rates of spinal cord ischemia were nonsignificantly higher in the stent group (P = .18). During follow-up (mean duration, 4.6 ± 3.6 y), computed tomography showed that stented patients more often had remodeling of the descending thoracic aorta (P = .0002) and somewhat more often had remodeling of the thoracoabdominal aorta (P = .13). Stented patients also had fewer subsequent procedures (P = .25). The 3- and 5-year survivals were 73.3% ± 6.9% and 49.9% ± 7.6% in the matched stented group and 66.3% ± 9.4% and 41.6% ± 7.7% in the matched standard group, respectively (P = .015 for overall survival).
CONCLUSIONS: In the short term, antegrade stent delivery was associated with less operative mortality. In the mid-term, promising remodeling of the false lumen was seen in stented patients, as were (nonsignificantly) lower rates of subsequent procedures in the thoracoabdominal aorta. Mid-term survival was also greater in the stented patients.
Copyright © 2019 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute type I aortic dissection; aortic arch surgery; aortic dissection; stenting; survival

Year:  2019        PMID: 30955955     DOI: 10.1016/j.jtcvs.2018.11.145

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

Review 1.  The frozen elephant trunk technique in acute DeBakey type I aortic dissection.

Authors:  Davut Çekmecelioğlu; Cüneyt Köksoy; Joseph Coselli
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-07-28       Impact factor: 0.332

2.  Distal Aortic Malperfusion Exacerbated by Antegrade Stent-Graft Placement During Hybrid Repair of Acute DeBakey Type I Aortic Dissection.

Authors:  Ross M Reul; Jonathan C Hong; Joseph S Coselli; Ourania Preventza
Journal:  Tex Heart Inst J       Date:  2022-07-01

Review 3.  Is Exercise Blood Pressure Putting the Brake on Exercise Rehabilitation after Acute Type A Aortic Dissection Surgery?

Authors:  Na Zhou; Warner M Mampuya; Marie-Christine Iliou
Journal:  J Clin Med       Date:  2022-05-23       Impact factor: 4.964

4.  Distal Aortic Remodeling after Type A Dissection Repair: An Ongoing Mirage.

Authors:  Kaushalendra Singh Rathore
Journal:  J Chest Surg       Date:  2021-12-05

5.  A modified frozen elephant trunk technique for acute Stanford type A aortic dissection.

Authors:  Shi-Bo Song; Xi-Jie Wu; Yong Sun; Shi-Hao Cai; Po-Yuan Hu; Hai-Feng Qiang
Journal:  J Cardiothorac Surg       Date:  2020-10-21       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.